BC Centre for Disease Control
An agency of the Provincial Health Services Authority

Immunization Programs and Vaccine
Preventable Diseases Service
655 West 12th Avenue
Vancouver, BC V5Z 4R4

Tel 604.707.2548
Fax 604.707.2515
www.bccdc.ca

Date: **May 15, 2017** **Administrative Circular:** **2017:07**

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2 - Immunization Program, Section IA-Introduction, Section IIA-Immunization Schedules, Section IIB-Contraindications and Precautions for Immunization & Section VII-Biological Products

Section IA-Introduction

11.0 History of Immunization in BC

- The table has been updated to include that Gardasil®9 replaces Gardasil® for all indications in May 2017.

Please remove page number: 29 dated September 2016
Please add new page number: 29 dated May 2017

Section IIA-Immunization Schedules

Vaccine Abbreviations and Vaccines

- HPV4 has been removed from the table as this vaccine is no longer being supplied in BC.

Please remove page number: 1 dated August 2016
Please add new page number: 1 dated May 2017

2.3 Schedule C & 2.4 Schedule D

- All references to the quadrivalent human papillomavirus vaccine (HPV4) have been removed as this vaccine is no longer being supplied in BC. Nonavalent human papillomavirus vaccine (HPV9) has replaced HPV4 for all indications.

Please remove page numbers: 6-9 dated January & August 2016
Please add new page numbers: 6-9 dated May 2017

3.1 Minimum Intervals Between Vaccine Doses Table

- Gardasil® has been removed from HPV vaccines.
- Nimenrix® has been added to meningococcal quadrivalent conjugate vaccines.

Please remove page number: 12 dated February 2017
Please add new page number: 12 dated May 2017

Section IIB-Contraindications and Precautions for Immunization

4.1 Latex Content in Vaccines

- Gardasil®, Meningitec®, Menomune® and Zostavax® have been removed as these vaccines are no longer supplied in BC.
- Nimenrix® has been added to the list of products that do not contain latex.

Please remove page number: 6 dated August 2016
Please add new page number: 6 dated May 2017

Section VII-Biological Products

Hepatitis A Vaccine (Havrix® 1440 and Havrix® 720 Junior)

- The concentration of the adult presentation has been corrected to indicate 1440 ELU/1.0 mL.

Please remove page number: 8 dated February 2017
Please add new page number: 8 dated May 2017

Human Papillomavirus Vaccine [Nonavalent (6, 11, 16, 18, 31, 33, 45, 52, and 58)]

- All references to the quadrivalent human papillomavirus vaccine (HPV4/Gardasil®) have been removed as this vaccine is no longer being supplied in BC. Nonavalent human papillomavirus vaccine (HPV9/Gardasil®9) has replaced HPV4/Gardasil® for all indications.
- DOSES AND SCHEDULE has been revised to include the dose and schedule information for immunocompromised individuals (including those with HIV infection) 9-14 years of age (inclusive), as this content was previously contained within a footnote. Content related to the timing of the initiation of the series has been moved to Footnote D.
- CONTRAINDICATIONS has been revised to indicate a history of an anaphylactic reaction to a previous dose of any HPV vaccine or to any component of GARDASIL®9.

Please remove page numbers: 24a-24c dated November 2016
Please add new page numbers: 24a & 24b dated May 2017

Meningococcal Quadrivalent Conjugate Vaccines (Groups A, C, Y, W-135)

- Nimenrix®, supplied by Pfizer Canada Inc., has been added to the product list.
- DOSES AND SCHEDULE has been updated to indicate that Nimenrix® is recommended for individuals 2 years of age and older.
- Footnote related to the transition of Menveo® from Novartis Vaccines and Diagnostics Inc. to GlaxoSmithKline Inc. has been removed as this transition is complete.
- Footnote F has been revised to indicate that a second dose of meningococcal quadrivalent conjugate vaccine may also be indicated for high risk individuals.
- ADMINISTRATION has been updated to indicate that Nimenrix® needs to be reconstituted.
- CONTRAINDICATIONS has been revised to indicate a history of anaphylactic reaction to a previous dose of any meningococcal vaccine or any component of the specific vaccine to be given.
- PRODUCT COMPONENTS has been updated to include Nimenrix® product components.
- ADVERSE EVENTS has been updated to include 'fatigue, irritability and loss of appetite'.

Please remove page numbers: 41-43 dated July 2016 & December 2015
Please add new page numbers: 41-43 dated May 2017

Rabies Vaccine for Post-Exposure Prophylaxis

- The supplier for RabAvert® has been revised to GlaxoSmithKline Inc.
- INDICATIONS has been revised as follows:
    - The contact information regarding with whom consultation is available has been changed from "Communicable Disease Prevention and Control Services, BCCDC" to "BCCDC".
    - "Administer RabIg on day 0 of vaccine series" has been removed as this information is contained in DOSES AND SCHEDULE.
- DOSES AND SCHEDULE content has been re-organized for clarity; the content remains unchanged.
- ADMINISTRATION has been revised as follows:
    - Content related to the preferred administration site as per the client's age has been removed as this information is contained in Section IV-Administration of Biological Products, and for consistency with other biological product pages.
    - Pertinent information related to the reconstitution of the products has been moved from RECONSTITUTION and SPECIAL CONSIDERATIONS to ADMINISTRATION.
    - Content related to the rabies vaccine and RabIg not being administered in the same anatomical site, as well as the use of separate needles and syringes for each product, has been moved from CONTRAINDICATIONS to ADMINISTRATION.
    - Content related to the immediate use of the vaccine following reconstitution has been moved from SPECIAL CONSIDERATIONS to ADMINISTRATION.
- RECONSTITUTION section has been removed as this information is contained in Section IV-Administration of Biological Products, and for consistency with other biological product pages.

- SEROLOGICAL TESTING AND RE-VACCINATION: associated footnote A has been updated to indicate that testing is conducted at the National Microbiology Laboratory.
- PRODUCT COMPONENTS has been updated.
- ADVERSE EVENTS has been updated to include 'myalgia, arthralgia, malaise and fever' for IMOVAX® Rabies, and 'fatigue' for RabAvert®.

Rabies Vaccine for PRE-EXPOSURE Prophylaxis

- The supplier for RabAvert® has been revised to GlaxoSmithKline Inc.
- INDICATIONS has been revised to mirror the indications in the CD Manual, Chapter 1: Rabies, along with the addition of 'bat biologists' to those for whom the vaccine is recommended but not provided free.
- DOSES AND SCHEDULE content has been re-organized for consistency with other biological product pages.
- ADMINISTRATION has been revised as follows:
    - Content related to the preferred administration site as per the client's age has been removed as this information is contained in Section IV-Administration of Biological Products, and for consistency with other biological product pages.
    - Pertinent information related to the reconstitution of the products has been moved from RECONSTITUTION and SPECIAL CONSIDERATIONS to ADMINISTRATION.
    - Content related to the immediate use of the vaccine following reconstitution has been moved from SPECIAL CONSIDERATIONS to ADMINISTRATION.
- RECONSTITUTION section has been removed as this information is contained in Section IV-Administration of Biological Products, and for consistency with other biological product pages.
- SEROLOGICAL TESTING AND RE-VACCINATION: associated footnote B has been updated to indicate that testing is conducted at the National Microbiology Laboratory.
- PRODUCT COMPONENTS has been updated.
- Content related to the consideration of an alternate administration route and dose volume in the event of a rabies vaccine shortage has been moved from ADMINISTRATION to SPECIAL CONSIDERATIONS.
- ADVERSE EVENTS has been updated to include 'myalgia, arthralgia, malaise and fever' for IMOVAX® Rabies, and 'fatigue' for RabAvert®.

Please remove page numbers: 55-58b dated May 2014
Please add new page numbers: 55-58b dated May 2017

Please also remove the Table of Contents for Section VII-Biological Products dated February 2017 and replace with the enclosed updated Table of Contents dated May 2017.

If you have any questions or concerns, please contact Christine Halpert, Senior Practice Leader, BCCDC (telephone: 604-707-2555 / email: christine.halpert@bccdc.ca) or Stephanie Meier, Public Health Resource Nurse, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca.)

Sincerely,

Monika Naus MD MHSc FRCPC FACPM
Medical Director
Immunization Programs and Vaccine Preventable Diseases Service
BC Centre for Disease Control

pc: BC Ministry of Health:
Dr. Perry Kendall
Provincial Health Officer

Dr. Bonnie Henry
Deputy Provincial Health Officer

Craig Thompson
Director, Provincial Immunization Services

Warren O'Briain
Executive Director, Public Health Services & Office of Aboriginal Health